Publications
-
December 1, 2017
Patient-Reported Outcome (PRO) Consortium Translation Process: Consensus Development of Updated Best Practices
Eremenco S, Pease S, Mann S, Berry P, on behalf of the PRO Consortium’s Process Subcommittee. Patient-Reported Outcome (PRO) Consortium translation process: consensus development of updated best practices. Journal of Patient-Reported Outcomes. 2017;(2):12.
-
November 24, 2017
Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development
Steinhorn R, Davis JM, Göpel W, Jobe A, Abman S, Laughon M, Bancalari E, Aschner J, Ballard R, Greenough A, Storari L, Thomson M, Ariagno RL, Fabbri L, Turner MA. Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development. The Journal of Pediatrics. 2017 Dec 1;191:15–21.e1.
-
November 22, 2017
What Evidence Do We Need for Biomarker Qualification?
Leptak C, Menetski JP, Wagner JA, Aubrecht J, Brady L, Brumfield M, Chin WW, Hoffmann S, Kelloff G, Lavezzari G, Ranganathan R, Sauer JM, Sistare FD, Zabka T, Wholley D. What Evidence Do We Need for Biomarker Qualification? Science Translational Medicine. 2017 Nov 22;9(417).
- October 31, 2017
-
October 26, 2017
226th ENMC International Workshop: Towards Validated and Qualified Biomarkers for Therapy Development for Duchenne Muscular Dystrophy
Aartsma-Rus A, Ferlini A, McNally EM, Spitali P, Sweeney HL, Aartsma-Rus AM, Szigyarto CAK, Bello L, Bronson A, Brown K, Buccella F, Chadwick J, Ferlini A, Frank D, Hoffman E, Larkindale J, McClorey G, McNally E, Munschauer R, Muntoni F, Owens J, Schara U, Spitali P, Straub V, Sweeney L, Tinsley J, Versnel J, Vroom E, Welch E. 226th ENMC International Workshop: Towards Validated and Qualified Biomarkers for Therapy Development for Duchenne Muscular Dystrophy. Neuromuscular Disorders. 2017 Oct.
